West Pharmaceutical Services (WST) cash flow statement

Health Care Supplies · NYSE · Health Care

$414.12 -0.88% Close Nov 17, 2026 Live

TrendArc score 67 of 100 · Health 7.6 · Momentum 8.8 · Moat 6.8 · scored Nov 17, 2026 · How the score works

Free cash flow, fiscal year to December 31, 2025

$469 million

up 69.6% from the year before

West Pharmaceutical Services generated $469 million of free cash flow in the fiscal year to December 2025: $755 million of cash from operations less $286 million of capital spending. That was 15.3% of revenue, against 9.6% the year before. Over the last four quarters, to September 30, 2026, it was $580 million.

What stands out

  • Over the five fiscal years to December 2025 it paid $1.7 billion in dividends and net share repurchases, 87% of its free cash flow over the same years.
  • Free cash flow was below net income in each of the last five fiscal years; in the fiscal year to December 2025 it was 95% of net income.
  • Cash dividends paid rose in each of the last five fiscal years, from $48 million to $61 million in total.

Each sentence is written by a fixed rule from the figures on this page.

Free cash flow and net income, the last 10 fiscal years

$200M$400M$600M$800M2016201720182019202020212022202320242025$49.2MFree cash flow $469MNet income $494M$200M$400M$600M$800M20172019202120232025Free cash flow $469MNet income $494M

Fiscal years, each labelled by the calendar year it ended in. Every figure is in the statement below.

Where the cash wentFiscal year to December 31, 2025

  1. Cash from operations 755
  2. Capital spending -286
  3. Free cash flow 469
  4. Net share repurchases -126
  5. Dividends -61
  6. Debt and other 25
  7. Net change in cash 307

In millions of US dollars. Outflows are grey, not red: a buyback is not a loss. "Debt and other" closes the gap to the reported change in cash. Buying marketable securities moves cash into short-term investments; the balance sheet shows both.

Cash flow statement, the last 10 fiscal years

In millions of US dollars. Each column is a fiscal year, named by the month it ended; the first column adds up the last four quarters. Cash paid out is a negative number.
Fiscal year toLast 4 quarters
to Sep 2026
Dec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
Operating activities
Net income494493593586662346242207151144
Depreciation and amortisation1711551371211221091031049791
Stock-based pay2924192324383424151620
Working capital and other items66-1323-6-238-17-2-380-34
Cash from operations655755653777724584473367289263219
Investing activities
Capital spending-74-286-377-362-285-253-174-126-105-131-170
Businesses bought and sold, net0000-20-1040-6-8
Investments bought and sold, net0000000000
Cash from investing-286-379-369-288-253-180-228-101-134-176
Financing activities
Debt issued or repaid, net-1-28-2-46-2-2610-35-70
Shares issued less bought back-669-126-541-407-201-123-93-58-43-39-30
Dividends paid-63-61-59-57-54-51-48-45-42-39-36
Other financing35778655422
Cash from financing-185-623-460-294-168-137-37-81-109-114
Exchange rate effect23-2111-11-1621-1-612-1
Net change in cash307-369-4013214717610210233-72
Free cash flow
Free cash flow58046927641543933129824118413349
Free cash flow margin17.1%15.3%9.6%14.1%15.2%11.7%13.9%13.1%10.7%8.3%3.3%
Free cash flow per share$6.45$3.75$5.50$5.80$4.33$3.93$3.19$2.44$1.75$0.66

Shares issued less bought back is the cash from shares sold less the cash paid for shares bought back (negative when more was bought back), and includes tax withheld when employees' shares vest. Working capital and other items is cash from operations less net income, depreciation and amortisation, and stock-based pay (calculated by TrendArc). Company filings as standardised by Tiingo; calculations by TrendArc. Rebuilt nightly.

West Pharmaceutical Services against its peers

CompanyFiscal year toFree cash flowFree cash flow margin
ResMedRMD Jun 2026$1.65B29.2%
DexcomDXCM Dec 2025$1.08B23.1%
IlluminaILMN Dec 2025$931M21.4%
Mettler ToledoMTD Dec 2025$849M21.1%
SterisSTE Mar 2026$983M16.6%
West Pharmaceutical ServicesWST Dec 2025$469M15.3%
IQVIAIQV Dec 2025$2.13B13.0%
GE HealthCareGEHC Dec 2025$1.50B7.3%
Peer median21.1%

Each company's newest fiscal year; some end in other months. The peers are the stock card's peer group.

Next

Follow West Pharmaceutical Services with a free account.

A watchlist, price alerts and saved chart layouts. No card needed.

Sign up free

No forecast, no recommendation. This page describes West Pharmaceutical Services from published data; it is not advice to buy, sell or hold any security.

Figures as of the close on Nov 17, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.

The TrendArc score, from 0 to 100, combines three pillars measured from published data, Health (business quality over the last twelve months), Momentum (the price against its moving averages, its 52-week high and the market) and Moat (durability over five years), with the share price's long-run trend. It describes the company as it stands today. It is not a forecast or a recommendation.